Abstract
One of the most important features of liver cirrhosis is the splanchnic and systemic arterial vasodilation, related to an increase in vascular capacity and an active vasodilation. This arterial vasodilation seems to be the consequence of the excessive generation of vasodilating substances, which also contributes to a lower than normal pressor response to circulating nervous or humoral substances. The following review analyzes the mechanisms responsible for the vascular hyporesponse to vasoconstrictors observed in the experimental models of liver cirrhosis. It has become increasingly clear that, among the great variety of substances studied, nitric oxide (NO) seems to be one of the main contributors to this vascular alteration, since elimination of the endothelium or inhibition of its synthesis corrects it. The mechanism by which NO interferes with the contractile apparatus in smooth muscle cells seems to be related to a direct effect on calcium entry from the extracellular space and release from the internal stores.
Keywords: endothelium, smooth muscle cells, nitric oxide, liver cirrhosis, vasoconstrictors, vasodilation, portal hypertension
Current Vascular Pharmacology
Title: Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis
Volume: 3 Issue: 1
Author(s): Noemi M. Atucha, F. Javi A. Nadal, David Iyu, Antonia Alcaraz, Alicia Rodriguez-Barbero, M. Clara Ortiz, Jose Miguel Lopez-Novoa and Joaquin Garcia-Estan
Affiliation:
Keywords: endothelium, smooth muscle cells, nitric oxide, liver cirrhosis, vasoconstrictors, vasodilation, portal hypertension
Abstract: One of the most important features of liver cirrhosis is the splanchnic and systemic arterial vasodilation, related to an increase in vascular capacity and an active vasodilation. This arterial vasodilation seems to be the consequence of the excessive generation of vasodilating substances, which also contributes to a lower than normal pressor response to circulating nervous or humoral substances. The following review analyzes the mechanisms responsible for the vascular hyporesponse to vasoconstrictors observed in the experimental models of liver cirrhosis. It has become increasingly clear that, among the great variety of substances studied, nitric oxide (NO) seems to be one of the main contributors to this vascular alteration, since elimination of the endothelium or inhibition of its synthesis corrects it. The mechanism by which NO interferes with the contractile apparatus in smooth muscle cells seems to be related to a direct effect on calcium entry from the extracellular space and release from the internal stores.
Export Options
About this article
Cite this article as:
Atucha M. Noemi, Nadal Javi A. F., Iyu David, Alcaraz Antonia, Rodriguez-Barbero Alicia, Ortiz Clara M., Lopez-Novoa Miguel Jose and Garcia-Estan Joaquin, Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773889
DOI https://dx.doi.org/10.2174/1570161052773889 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiocontrast Nephropathy: Progress not Prevention
Current Cardiology Reviews Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Biological and Pharmacological Activities of Carvacrol and Carvacrol Bearing Essential Oils
Current Pharmaceutical Design Disease Modification in Rheumatoid Arthritis and Osteoarthritis-Current and Emerging Targets and Therapeutics
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Sepsis: The Involvement of Platelets and the Current Treatments
Current Molecular Pharmacology Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease
Current Clinical Pharmacology Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Theoretical and Evidence-Based Benefit of Afterload Reduction in the Postoperative Pediatric Heart
Current Vascular Pharmacology Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery